You are here
Bone Metastases: recommendations and survival
By Robert Coleman, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris
Supportive care measures can sometimes change the outcome of the underlying disease; one such example is the notion of bone protection which is quite important in modifying the metastatic process as the bone marrow microenvironment plays a central role in tumour dormancy and metastasis. Robert Coleman speaks about the use of bone protection in its classic sense, i.e. to prevent cancer treatment-induced bone loss, as well as the manipulation of the bone microenvironment by bone-targeted drugs. Bisphosphonates are a class of drugs used to treat hypercalcemia and prevent skeletal morbidity; however, adjuvant bisphosphonates also reduce bone metastases and improve survival. Robert Coleman presents data of recent meta-analyses which suggest that patients should receive bisphosphonates not only for their bone protection, but also for their anti-cancer effects.
Robert Coleman, University of Sheffield, UK